C9098 Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short descriptor: Ciltacabtagene car pos t
Look up C9098 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
C9098 is the HCPCS Level II code for Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (2026). It belongs to Section C — Outpatient PPS (Hospital). Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Statute.
Classification & CMS Attributes
- Section
- C: Outpatient PPS (Hospital)
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Statute (indicator 53)
- Type of Service
- Medical care
- Effective Date
- 2022-10-01
- Termination Date
- 2022-09-30
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference C9098 with the canonical source and edition:
C9098 — Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/C9098
Canonical URL: https://icd10codingpro.com/hcpcs-codes/C9098